MedTrace Logo

Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients

NCT04450108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-06-06

Study results available
· View outcomes & findings →

Summary

This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.

Conditions

Interventions

DIAGNOSTIC_TEST

Vivatmo pro FeNO Test

Breath gas analysis

Sponsors & Collaborators

  • Global BioClinical

    collaborator INDUSTRY

  • Bosch Healthcare Solutions GmbH

    lead INDUSTRY

Principal Investigators

  • Klaus Mueller · Bosch Healthcare

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-08
Primary Completion
2020-12-18
Completion
2021-04-13
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04450108 on ClinicalTrials.gov